Slide 1: Investor Presentation Q4 FY16 Earnings Release
Investor Presentation Q4 FY 16 Earnings Release 24 May 2016 Investor Presentation Q4 FY 16 Earnings Release Confidential 1
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 3: Financial Performance
Financial Performance Q4 FY 2015-16 FY 2015-16 Consolidated Consolidated Actuals vs Q4 FY Actuals vs FY 15 (Rs Cr.) 15 (Rs Cr.) Revenue 3,267 5.6% 13,678 20.6% Domestic Sales 1,258 15.9% 5,111 5.9% Export Sales 1,948 2.8% 8,261 36.4% EBITDA 219 -56.9% 2,501 15.7% EBITDA % 6.7% -9.7% 18.3% -0.8% PAT
Slide 4: Base business EBITDA margin level of ~16%
Base business EBITDA margin level of ~16% Q4 FY 2014-15 Q4 FY 2015-16 Reported EBITDA (Rs. Crore) 508 219 EBITDA Margin (%) 16.4% 6.7% Adjustments (%) - ~1.3% Non-moving inventory write-off Inventory reduction - ~2.1% Complexity reduction – restructuring and - ~2.1% rationalization Other one-offs (p
Slide 5: India (Rx and Gx)
India (Rx and Gx) India FY Sales (Rx and Gx)1 Domestic business contribution at ~40% of overall sales, of which Rx sales accounted for 81% Rs. crore Strong domestic performance relative to market 6000 – Growth of 16% vs. market growth of 14%2 5184 Ranked #3 in IPM, with a market share of 5.3%2
Slide 6: South Africa
South Africa South Africa FY Sales South Africa contribution at ~11.5% of overall sales ZAR Mn Overall sales growth of ~25% in FY 2015-16, vs. last year 3500 3272 Growth of 14% in private market, driven by outperformance of base business and new 3000 25% business 2613 – Leadership in Respirato
Slide 7: North America
North America North America FY Sales North America business contribution of ~15% to overall sales (including acquisitions) $ Mn Accelerated sales growth driven by Esomeprazole launch in FY 2015-16 350 321.4* 5 filings in FY 2015-16, 3 products approved and/ or launched (from own pipeline) 300
Slide 8: International
International International FY Sales International business contribution at ~25% of overall sales $ Mn Overall growth of ~14% in International business in FY 2015-16, vs. last year 600 Robust growth of ~25% in front-end markets vs. 522.5 last year, despite Yemen war situation and 500 459.1 14%
Slide 9: Europe and API
Europe and API Europe FY Sales Europe business contribution of ~4% to overall sales $ Mn Growth of 30% in FY 2015-16 sales vs. last year, 120 driven by strong performance across B2B and 100 92 DTM segments 80 70.6 30% Launch of Fluticasone Salmeterol, Mometasone, 60 Fluticasone, Ipratropium Sa
Slide 10: Key priorities going forward to deliver the next phase of growth
Key priorities going forward to deliver the next phase of growth Key Priorities Strategy Enhance scale of US DTM play through seamless integration of InvaGen and Exelan businesses - Launch 5-7 products in InvaGen pipeline (Nadolol already launched) Accelerate scale-up - Launch 8-10 products from C